Physician profile
Andre T Le
NPI 1073566022
$14,762.48
in general payments reported to CMS, 2019-2025
26 companies · $503 in 2025
The $503 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,228 · 2020: $6,633 · 2021: $924 · 2022: $402 · 2023: $503 · 2024: $570 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555 · Entertainment: $20.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.34 |
| Entertainment | $20.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $11,107.10 | 2019-2025 | Cequa |
| Alcon Vision LLC | $1,611.22 | 2019-2025 | Precision7, Dailies Total1, Precision 1 |
| Sight Sciences, INC. | $223.97 | 2020-2024 | Omni Surgical System, Tearcare System |
| Integra Lifesciences Corporation | $215.05 | 2019-2022 | |
| Maculogix, INC. | $195.00 | 2019-2020 | |
| Lumenis Be INC | $168.50 | 2023 | Optilight |
| Kala Pharmaceuticals, INC. | $153.90 | 2021 | |
| Oyster Point Pharma, INC. | $144.56 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $114.44 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $110.78 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $104.17 | 2020 | |
| Abbvie INC. | $99.75 | 2022-2024 | |
| Eyevance Pharmaceuticals LLC | $78.29 | 2021-2022 | |
| Derma Sciences, INC. | $73.50 | 2019 | |
| Dompe US, INC. | $71.87 | 2025 | Oxervate |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $42.49 | 2019 | |
| Carl Zeiss Meditec, INC. | $35.53 | 2019 | |
| Coopervision INC. | $34.16 | 2022-2023 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $32.17 | 2025 | |
| Biotissue Holdings INC. | $30.96 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.57 | 2020 | |
| Optos, INC. | $20.43 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Thea Pharma INC. | $20.09 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $19.32 | 2022 | |
| Horizon Therapeutics Plc | $15.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.